Table 3.

Hazard ratios for mortality comparing patients who underwent CROSS inside a trial (reference) with patients treated in the post-CROSS era

	HR	95% CI	p value
30-day mortality	1.37	0.40–4.68	0.62
90-day mortality	0.53	0.23–1.25	0.15
Overall survival	1.02	0.75–1.39	0.90
Disease-free survival	0.93	0.67–1.31	0.69

CROSS ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study, HR hazard ratio, CI confidence interval